Formation of an F2-isoprostane in vascular smooth muscle cells by elevated glucose and growth factors

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 271, Issue 1 40-1, 1996, Pages

  Natarajan, Rama ^a   Lanting, Linda ^a   Gonzales, Noe ^a   Nadler, Jerry ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

angiotensin II; diabetes; oxidative stress; platelet derived growth factor; transforming growth factor

Indexed keywords

ANGIOTENSIN; CELL PROTEIN; GLUCOSE; GROWTH FACTOR; PROSTAGLANDIN F2 ALPHA; 8 EPI PROSTAGLANDIN F2ALPHA; 8-EPI-PROSTAGLANDIN F2ALPHA; ANGIOTENSIN II; ANTIOXIDANT; DRUG DERIVATIVE; GROWTH PROMOTOR; ISOPROSTANE DERIVATIVE; MEPACRINE; PHOSPHOLIPASE A; PLATELET DERIVED GROWTH FACTOR; PYRROLIDINE DERIVATIVE; PYRROLIDINE DITHIOCARBAMIC ACID; THIOCARBAMIC ACID DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ARTICLE; CELL GROWTH; CONTROLLED STUDY; CULTURE MEDIUM; GLUCOSE METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN DETERMINATION; SWINE; VASCULAR SMOOTH MUSCLE; ANIMAL; BIOSYNTHESIS; CELL CULTURE; CELL DIVISION; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; TIME;

ANGIOTENSIN II; ANIMALS; ANTIOXIDANTS; CELL DIVISION; CELLS, CULTURED; DINOPROST; F2-ISOPROSTANES; GLUCOSE; GROWTH SUBSTANCES; MUSCLE, SMOOTH, VASCULAR; PHOSPHOLIPASES A; PLATELET-DERIVED GROWTH FACTOR; PYRROLIDINES; QUINACRINE; SWINE; THIOCARBAMATES; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 33750834897     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.1996.271.1.h159     Document Type: Article

References (40)

1. Altomare, E., G. Vendemiale, D. Chiocco, V. Procacci, and F. Cirelli. Increased lipid peroxidation in type 2 poorly controlled diabetic patients. Diabete Metab. 18: 264-271, 1992.
2. Baas, A. S., and B. C. Berk. Oxidative stress stimulates mitogen-activated protein kinases in vascular smooth muscle cells (Abstract). J. Invest. Med. 43: 206, 1995.
3. Banerjee, M., K. H. Kang, J. D. Morrow, J. L. Roberts, and J. H. Newman. Effects of a novel prostaglandin, 8-epi-PGF2α, in rabbit lung in situ. Am. J. Physiol. 263 (Heart Circ. Physiol. 32): H660-H663, 1992.
4. Berk, B. C., V. Vekshtein, H. M. Gordon, and T. Tsuda. Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension Dallas 13: 305-314, 1989.
5. Bucala, R., Z. Makita, T. Koschinsky, A. Cerami, and H. Vlassara. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc. Natl. Acad. Sci. USA 90: 6434-6438, 1993.
6. Carew, T. E., D. C. Schwenke, and D. Steinberg. Antiatherogenic effects of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low-density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the WHHL rabbit. Proc. Natl. Acad. Sci. USA 84: 7725-7729, 1987.
7. Freychuss, A., A. Stiko-Rahm, J. Swedenborg, P. Henriksson, I. Bjorkhem, L. Berglund, and N. Nilsson. Antioxidant treatment inhibits the development of intimai thickening after balloon injury of the aorta in hypercholesteroiemic rabbits. J. Clin. Invest. 91: 1282-1288, 1993.
8. 2-isoprostane receptors on rat vascular smooth muscle cells. Am. J. Physiol. 264 (Cell Physiol. 33): C1619-C1624, 1993.
9. Geisterfer, A. A. T., M. J. Peach, and G. K. Owens. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ. Res. 62: 749-756, 1988.
10. 2α levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett. 368: 225-229, 1995.
11. 2-isoprostanes during the oxidative modification of low-density lipoprotein. Biochem. Biophys. Res. Commun. 200: 338-343, 1994.
12. 2-isoprostanes during aortic endothelial cell-mediated oxidation of low-density lipoprotein. FEBS Lett. 348: 297-300, 1994.
13. Griendling, K. K., C. A. Minieri, J. D. Ollenshaw, and R. W. Alexander. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 74: 1141-1148, 1994.
14. 2α in the airways of human subjects. Am. J. Respir. Cell Mol. Biol. 9: 568-572, 1993.
15. Jain, S. K., R. Mcvie, J. Duett, and J. J. Herbst. Erythrocyte membrane lipid peroxidation and glycosylated hemoglobin in diabetes. Diabetes 38: 1539-1543, 1989.
16. Kannan, K., and S. K. Jain. Effect of high glucose on cellular proliferation and lipid peroxidation in cultured Vero cells. Horm. Metab. Res. 26: 322-320, 1993.
17. Kawahara, Y., K. Kariya, S. Araki, H. Fukuzaki, and Y. Takai. PDGF-induced phospholipase C-mediated hydrolysis of phosphoinositides in vascular smooth muscle cells: different sensitivity of PDGF and angiotensin II-induced phospholipase C reactions to protein kinase C-activating phorbol esters. Biochem. Biophys. Res. Commun. 156: 846-854, 1988.
18. Khan, B. V., S. Parthasarathy, M. T. Olbrych, R. W. Alexander, and R. M. Medford. Redox-sensitive activation of endothelial VCAM expression by angiotensin II (Abstract). J. Invest. Med. 43: 246.
19. 2-isoprostanes) in plasma and low-density lipoprotein exposed to oxidative stress in vitro. J. Clin. Invest. 93: 998-1004, 1994.
20. Marnett, L. J., P. Wlodawer, and B. Samuelsson. Co-oxygenation of organic substrates by the prostaglandin synthase of sheep vascular gland. J. Biol. Chem. 250: 8510-8517, 1975.
21. 2α (8-isoprostane), a novel marker of lipid peroxidation, is elevated and inversely correlated to serum antioxidant vitamins in smokers (Abstract). Clin. Res. 42: 366, 1994.
22. 2-isoprostanes) are formed in situ on phospholipids. Proc. Natl. Acad. Sci. USA 89: 10721-10725; 1992.
23. 2-isoprostanes) in carbon tetrachloride hepatotoxicity. An animal model of lipid peroxidation. J. Clin. Invest. 90: 2502-2507, 1992.
24. 2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical catalyzed mechanism. Proc. Natl. Acad. Sci. USA 87: 9383-9387; 1990.
25. 2α, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/ endoperoxide receptor antagonist. Prostaglandins 44: 155-163, 1992.
26. Morrow, J. D., and J. D. Roberts II. Quantification of non-cyclooxygenase derived prostanoids as a marker of oxidative stress. Free Rad. Biol. Med. 10: 195-200, 1991.
27. Mullarkey, C. J., D. Edelstein, and M. Brownlee. Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem. Biophys. Res. Commun. 173: 932-939, 1990.
28. Natarajan, R., W. Bai, J. L. Gu, V. Rangarajan, N. Gonzales, and J. Nadler. Platelet-derived growth factor is a potent regulator of 12-lipozygenase activity and expression in vascular smooth muscle cells (Abstract). Clin. Res. 42: 177, 1994.
29. Natarajan, R., N. Gonzales, L. Lanting, and J. Nadler. Role of the lipoxygenase pathway in angiotensin II-induced vascular smooth muscle cell hypertrophy. Hypertension Dallas 23, Suppl. I:I-142-I-147, 1994.
30. Natarajan, R., N. Gonzales, L. Xu, and J. Nadler. Vascular smooth muscle cells exhibit increased growth in response to elevated glucose. Biochem. Biophys. Res. Commun. 187: 552-560, 1992.
31. Natarajan, R., J. L. Gu, J. Rossi, N. Gonzales, L. Lanting, L. Xu, and J. Nadler. Elevated glucose and angiotensin II increase 12-lipoxygenase activity and expression in porcine aortic smooth muscle cells. Proc. Natl. Acad. Sci. USA 90: 4947-4951, 1993.
32. Rajeswari, P., R. Natarajan, J. Nadler, D. Kumar, and V. K. K. Kalra. Glucose induces lipid peroxidation and inactivation of membrane-associated ion-transport enzymes in human erythrocytes in vivo and in vitro. J. Cell. Physiol. 149: 100-109, 1991.
33. Rao, G. N., and B. C. Berk. Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ. Res. 70: 593-599, 1992.
34. Roe, M. W., J. R. Hepler, T. K. Harden, and B. Herman. Platelet-derived growth factor and angiotensin II cause increases in cytosolic free calcium by different mechanisms in vascular smooth muscle cells. J. Cell. Physiol. 139: 100-108, 1989.
35. Ross, R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature Lond. 362: 801-809, 1993.
36. Steinberg, D. S., S. Parthasarathy, T. E. Carew, J. C. Khoo, and J. L. Witzum. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenecity. N. Engl. J. Med. 320: 915-924, 1989.
37. Stern, A. Oxidative Stress and Growth Factor-Mediated Signal Transduction. Oxidative Stress, Cell Activation and Viral Infection, edited by C. Pasquier. Basel, Switzerland: Bïrkhauser, 1994, p. 35-40.
38. 2α, in the rat. J. Clin. Invest. 90: 136-141, 1992.
39. Williams, B., P. Tsai, and R. W. Schrier. Glucose-induced downregulation of angiotensin II and arginine vasopressin receptors in cultured rat aortic vascular smooth muscle cells. J. Clin. Invest. 90: 1992-1999, 1992.
40. Wolff, S. P., and R. T. Dean. Glucose autooxidation and protein modification. The potential role of autooxidative glycosylation in diabetes. Biochem. J. 245: 243-250, 1988.